APO-1 is a cell surface molecule that induces apoptosis when
T B-cell pool, is determined by the number of cells entering and leaving the system per unit time. In mice, about 10 million B cells, a number representing about one-tenth of the peripheral B-cell pool, are generated every day and migrate into the peripheral lymphoid organs.' To maintain a dynamic equilibrium, an equal number of cells has to be removed from the system. This elimination is so far only poorly understood. Recently, Liu et a12 provided evidence that the elimination of B cells takes place in the germinal centers of lymphoid follicles. These investigators showed that germinal center B cells, in contrast to other B cells, undergo apoptosis, a physiologic form of programmed cell death, unless they are stimulated via their antigen receptor and the CD40 molecule. High-affinity binding of surface Ig to antigen in the germinal center can therefore rescue specific B-cell clones from undergoing programmed cell death. Because most clones do not receive such an activation signal, apoptosis represents an important mechanism for the elimination of cells in vivo.
Another system has recently been described that shows that B cells enter apoptosis not only when a positive signal is missing but also when the APO-1 molecule on the surface is crosslinked by the monoclonal antibody (MoAb) anti-APO-1. The APO-1 antigen is a membrane antigen of approximately 50 Kd and is expressed on a number of cell lines and on activated T and B cell^.^^^ Recent cloning and sequencing of a cDNA coding for APO-1 has shown its identity to the Fas antigen.4a,5f6 APO-l/Fas is thus a novel cell surface receptor belonging to the family of receptors that includes nerve growth factor receptor, the B-cell antigen CD40, and the tumor necrosis factor (TNF) receptors. 6 Two models may account for APO-1-mediated apoptos k 4 APO-1 may represent a receptor that delivers an active apoptosis signal and may thus be involved in controlling the elimination of B cells and other APO-l-expressing cells. Alternatively, APO-1 may represent a growth factor receptor for a ligand that is essential for survival, and binding of the MoAb may prevent the ligand from binding to its receptor.
Burkitt's lymphoma (BL) is a human B-cell malignancy with characteristic epidemiologic features. The tumor is frequent in children in equatorial Africa and New Guinea and occurs with a lesser incidence all over the world. Almost all tumors from high incidence areas are EpsteinBarr virus (EBV)-positive, whereas only about 15% of tumors from low-incidence areas are associated with EBV.' EBV-positive and -negative tumors have an identical phenotype invivo with respect to CD10+, CD21-, CD23-, CD30-, CD39-, CD70-, CD77+ (BL group I phenotype; see Table  1 ). Cells with this phenotype are also found in the germinal centers of normal lymphoid tissue, suggesting that BL cells represent the malignant counterpart of this cell population.* From BL cases, cell lines can be established in vitro with a relatively high success rate. Usually EBV-negative cases give rise to cell lines that grow in single cell suspension and whose in vitro phenotype closely resembles that of the Table 1 ).l0J1 The change in growth pattern and phenotype is caused by an activation of EBV latent genes.t1J2 In cells with group I11 phenotype, at least six nuclear viral antigens (EBNA1,2,3a, 3b, 3c, EBNA-LP) and three membrane antigens are expressed (LMP, TP1, TP2), whereas group I cells express only the EBNAl antigen.
EBV-negative and EBV-positive BL cell lines that have maintained the group I phenotype in vitro grow rapidly under optimal growth conditions. They are, however, very sensitive to the withdrawal of autocrine or exogenous growth factors and readily undergo apoptosis, whereas EBV-positive BL group I11 cell lines tend to be resistant13 (M. Falk, unpublished observation). We were interested to see whether the susceptibility versus resistance of BL cells to apoptosis is related to the presence or absence of the APO-1 antigen. Therefore, we investigated the expression of N O -1 in a number of representative BL cell lines, as well as on fresh BL cell biopsies and normal EBVimmortalized lymphoblastoid cell lines. fetal calf serum (FCS), 100 pg/mL penicillin, 50 pg/mL streptomycin, 1 mg/mL amphotericin B, and were free of mycoplasma as judged by hybridization with a probe specific for mycoplasma microsomal RNA. Cells were kept at 37°C in a humidified atmosphere with 5% CO2. For indirect immunofluorescence for APO-1, lo6 cells were washed twice, resuspended in 0.1 mL of 1 pg/mL anti-NO-1 (1gG3,~) or FII23 (an 1gG3,~ nonbinding control antibody), incubated in 0.1% NaN3 for 30 minutes on ice, then washed twice, resuspended in 0.05 mL of 1:40 diluted fluorescein isothiocyanate (F1TC)-conjugated goat-antimouse IgG (Dianova, Hamburg, Germany), incubated for 30 minutes on ice, washed again twice, and analyzed on a FACScan or a FACStar Plus I1 (Becton Dickinson, Heidelberg, Germany). A suspension of fresh tumor cells was obtained by mincing a piece of tissue through a sieve followed by two washes. Washing and incubation steps were performed in RPMI with 10% FCS. FACS staining was performed at least twice.
MATERIALS AND METHODS

Cell
For each lane, lo6 cells were resuspended in 16 pL 50 mmol/L Tris, pH 6.8,20 mmol/L EDTA, 0.5% Triton-X-100, 2 mmol/L phenylmethylsulfonyl fluoride (PMSF), incubated 30 minutes on ice, and centrifuged for 15 minutes at 6,000g. The supernatant was adjusted to a final concentration of 10% glycerol, 2% sodium dodecyl sulfate (SDS), and separated on a nonreducing discontinuous 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE and immunoblotting on Immobilon membrane (Millipore, Eschborn, Germany) were performed following standard procedures." For detection of APO-1, blots were incubated for 16 hours at 4°C with anti-APO-1 hybridoma supernatant or isotype-matched control antibody, washed, and incubated for 2 hours at 18°C with peroxidase-conjugated rabbit-antimouse IgG antibody (Dakopatts, Copenhagen, Denmark). Staining was performed using a chemiluminescence system (ECL-system; Amersham, Braunschweig, Germany) following the instructions of the manufacturer.
Anti-APO-I-induced inhibition of cell proliferation. Cells (6 x l@/per 200 pL) were incubated in flat-bottomed 96-well plates (Falcon; Becton Dickenson, Heidelberg, Germany) in duplicates in either the presence of anti-NO-1 (1 ng/mL to 1 pg/mL) or in RPMI with FII23 control antibody (1 pg/mL) for 2 days. Cells were then pulsed with 0.5 pCi/well 3H-thymidine (Amersham) for 16 hours, harvested on a Titertek cell harvester on filter mates (Flow, Meckenheim, Germany), and counted in a liquid scintillation counter (Beckman, Miinchen, Germany). All functional assays were performed at least twice. Because crosslinking by protein A increases the sensitivity of anti-APO-1-mediated apoptosis$ all assays were performed in the presence of 5 pg/mL protein A (Sigma, Munchen, Germany). Medium controls as well as control antibody showed no effect on 3H-thymidine incorporation in all cell lines. Results were expressed as mean 3H-thymidine incorporation compared with control antibody.
Staining with anti-APO-1. (Fig 2) .
Western blotting.
RESULTS
APO-1 is not expressed
APO-1 expression was also studied by Western blotting. Using membranc-cnriched cell lysates. a band of approximately 48 Kd was visualized in all BL group 111 lines and LCLs were studied after incubation with anti-APO-1 antibodies (Fig 3A) , but not with isotype-matched control antibody (data not shown). Slight size variations might be due to differential glycosylation or to different amounts of contaminating protein in the extracts. The different intensities of the bands indicate different amounts of APO-1 in the extracts. The weak bands of lower molecular weight probably represent degradation products of APO-1.
APO-I is induced in B95-8 vim-converted cell lines. positive LCLs tested responded to the growth inhibitory effect of the MoAb, although to a lesser extent than SKW6.4 cells. For most lymphoblastoid cell lines, a 10-fold higher concentration of anti-APO-1 antibody was required to block proliferation completely compared with SKW6.4 cells (lower panel of Fig 5) . The BL group 111 lines were an exception. Although they expressed the APO-1 antigen at a level comparable with LCLs (Figs 1 and 3A) , 6 of 7 cell lines tested showed no reduction of proliferation when exposed to anti-APO-1 at concentrations up to 1 pg/mL. Four representative cell lines are shown in Fig 5. To rule out the possibility that BL group 111 lines showed a delayed response to anti-APO-1, proliferation was measured up to day 5 after addition of the antibody. Prolonged exposure to anti-APO-1 did not result in inhibition of proliferation in BLgroup 111 lines (data not shown).
Only one BL group I11 line (BL 74) showed moderate inhibition of proliferation in response to anti-APO-1. Another exception with regard to anti-APO-1 sensitivity was the B95-8 virus-convertant line of BL41 cells (Fig 4) . This cell line proved to be highly susceptible to APO-1-mediated apoptosis, in contrast to 5 othcr B95-8 virusconvertant lines (data not shown). A shift towards an activated phenotype is frequently observed upon establishment of EBV-positive BL cells in culture as a consequence of EBV latent gene activation. This shift to a group I11 phenotype (Table 1) however, does also increase CD23 expression in EBVnegative cells,21 suggesting that EBNA2 and LMP may cooperate in switching on the activation markers. The recent finding that EBNA3C also upregulates CD23 expression points, in fact, to a more complex regulation in which many of the latent viral gene products might be inv01ved.I~ It will therefore be important to understand how the various viral gene products interact at a molecular level with respect to regulation of expression of the cellular activation markers.
Although BL group I11 lines showed the same APO-1 staining pattern as EBV-immortalized LCLs, they behaved quite differently when the biologic activity of the antibody was studied. Growth inhibition by anti-APO-1 antibody is easily measurable in a quantitative fashion and was therefore taken as an indicator of induction of apoptosis by the antibody. As expected, cell lines that were negative for APO-1 staining did not respond to anti-APO-1 antibody. The reverse, however, was not true. Of the EBV-positive, APO-l-expressing group I11 BL lines, only BL74 responded to anti-APO-1, and only to a lesser extent than EBV-immortalized LCLs. Of 10 LCLs tested, all were sensitive to the action of the antibody.
The possibility of dissociating APO-1 expression from APO-1 function has also been described for T cells.4 This may turn out to be important for dissecting the various steps in the signal transduction pathway. An interesting possibility, which might explain the different sensitivity of EBVimmortalized LCLs and group I11 BL lines to APO-1 antibody, is that c-myc overexpression may interfere intracellularly with the delivery of the APO-1 signal in BL cells. Alternatively, following the model that APO-1 is a growth factor receptor, the c-myc translocation may have rendered the cells independent from a growth or survival factor that is absolutely required for lymphoblastoid cells. By introducing an activated c-myc gene into lymphoblastoid cells such as SKW6.4, the possible influence of this oncogene can now be tested.
EBV The data in this report show that the inherent susceptibility of BL cells to apoptosis is not correlated to the expression of the APO-1 antigen. APO-1 is not found in BL cells that undergo apoptosis upon removal of a positive signal and is induced in LCLs that have lost spontaneous susceptibility to apoptosis upon removal of growth factors.
Further insight into the biology of APO-1 and its role in the B-cell system is necessary to answer the crucial question of whether natural binding of a putative ligand to APO-1 induces cell death or cell survival.
